학술논문

EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling
Document Type
article
Source
Molecular Cell. 60(2)
Subject
Biochemistry and Cell Biology
Biomedical and Clinical Sciences
Biological Sciences
Clinical Sciences
Oncology and Carcinogenesis
Brain Disorders
Human Genome
Genetics
Brain Cancer
Cancer
Neurosciences
Rare Diseases
Aetiology
2.1 Biological and endogenous factors
Adult
Animals
Azepines
Brain Neoplasms
Cell Line
Tumor
Cell Survival
Cell Transformation
Neoplastic
Child
Epigenesis
Genetic
ErbB Receptors
Forkhead Transcription Factors
Gene Expression Regulation
Neoplastic
Gene Regulatory Networks
Glioblastoma
Humans
Mice
Mice
Nude
Mutation
Neoplasm Transplantation
Nerve Tissue Proteins
SOX9 Transcription Factor
Signal Transduction
Transcriptome
Triazoles
Medical and Health Sciences
Developmental Biology
Biological sciences
Biomedical and clinical sciences
Health sciences
Language
Abstract
Epidermal growth factor receptor (EGFR) gene amplification and mutations are the most common oncogenic events in glioblastoma (GBM), but the mechanisms by which they promote aggressive tumor growth are not well understood. Here, through integrated epigenome and transcriptome analyses of cell lines, genotyped clinical samples, and TCGA data, we show that EGFR mutations remodel the activated enhancer landscape of GBM, promoting tumorigenesis through a SOX9 and FOXG1-dependent transcriptional regulatory network in vitro and in vivo. The most common EGFR mutation, EGFRvIII, sensitizes GBM cells to the BET-bromodomain inhibitor JQ1 in a SOX9, FOXG1-dependent manner. These results identify the role of transcriptional/epigenetic remodeling in EGFR-dependent pathogenesis and suggest a mechanistic basis for epigenetic therapy.